The Immunomodulating Effect of Interferon-γ Intravesical Instillations in Preventing Bladder Cancer Recurrence

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5550-5558

  Giannopoulos, Aris ^a,d   Constantinides, Constantinos ^a   Fokaeas, Eleftherios ^b   Stravodimos, Constantinos ^a   Giannopoulou, Myrto ^a   Kyroudi, Aspasia ^a   Gounaris, Antonia ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c G Papanikolaou Research Centre   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MITOMYCIN C; MITOMYCIN C KYOWA; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLADDER CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; CYTOTOXIC T LYMPHOCYTE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATURAL KILLER CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SUPERFICIAL CANCER; T LYMPHOCYTE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; FEMALE; HUMANS; INSTILLATION, DRUG; INTERFERON TYPE II; MALE; MIDDLE AGED; MITOMYCIN; RECURRENCE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0344198121     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Baselli, E. C., and Greenberg R. E. Intravesical therapy for superficial bladder cancer. Oncology, 14: 719-729; discussion 729-731, 734-737, 2000.
2. Alexandroff, B. A., Jackson, M. A., O' Donnell, M. A., and James, K. BCG immunotherapy of bladder cancer: 20 years on review. Lancet. 353: 1689-1694, 1999.
3. Lamm, D. L., Riggs, D. R., Traynelis, C. L., and Nseyo, U. O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol., 153: 1444-1450, 1995.
4. Patard, J. J., Saint, F., Velotti, F., Abbou, C. C., and Chopin, D. K. Immune response following intravesical Bacillus Callmette-Guerin instillations in superficial bladder cancer: a review. Urol. Res., 26: 155-159, 1998.
5. Fleischmann, W. R., and Fleischmann, C. M. Mechanisms of interferons antitumor actions, in interferon: principles and medical applications. S. Baron et al. (ed.), pp. 289-298. Galveston, TX: The University of Texas, 1992.
6. Stavropoulos, N. E., Ioachim, E., Pavlidis, N., Pappa, L., Kalomiris, P., and Agnantis, N. J. Local immune response after intravesical interferon γ in superficial bladder cancer. Br. J. Urol., 81: 875-879, 1998.
7. Stravropoulos, N. E., Ioachim, E., Pappa, L., Hastatzeris, K., and Agnantis, N. J. Antiproliferative activity of interferon γ in superficial bladder cancer. Anticancer Res., 19: 4529-4533, 1999.
8. Pages, F., Lebel-Binay, S., Vieillefond, A., Deneux, L., Cambillau, M., Soubrane, O., Debre, B., Tardy, D., Romet Lemonne, J. L., Abastado, J. P., Fridman, W. H., and Thiounn, N. Local immunostimulation induced by intravesical administration of autologous interferon γ-activated macrophages in patients with superficial bladder cancer. Clin. Exp. Immunol., 127: 303-309, 2002.
9. Stravropoulos, N. E., Hastazeris, K., Filiadis, I., Mihailidis, I., Ioachim, E., Liamis, Z., and Kalomiris, P. Intravesical instillations of interferon γ in the proplylaxis of high risk superficial bladder cancer. Scand. J. Urol. Nephrol., 36: 218-222, 2002.
10. Hawkyard, S. J., Jackson, A. M., James, K., Prescott, S., Smyth, J. F., and Chisholm, G. D. The inhibitory effects of IFN-γ on the growth of bladder cancer cells. J. Urol., 147: 1399-1403, 1992.
11. Hawkyard, S. J., James, K., Prescott, S., Jackson, A. M., Ritchie, A. W., Smyth, J. F., and Chisholm, G. D. The effect of recombinant cytokines on bladder cancer cells in vitro. J. Urol., 150: 514-518, 1993.
12. Rintala, E., Jauhiainen, K., Rajala, P., Ruutu, M., Kaasinen, E., Alfthan, O., and Finnbladder Group. Alternating mitomycin C and Bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J. Urol., 156: 56-60, 1996.
13. Baxevanis, C. N., Dedoussis, G. V. Z., Papadopoulos, N. G., Missitzis, I., Stathopoulos, G., and Papamichail, M. Tumor-specific cytolysis by tumor-infiltrating lymphocytes in breast cancer. Cancer (Phila.), 74: 1275-1281, 1994.
14. Papadopoulos, N. G., Dedoussis, G. V. Z., and Spanakos, G. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow-cytometry. J. Immunol. Methods, 177: 101-111, 1994.
15. Sprent, P. Applied nonparametric statistical methods, Ed. 2, pp. 39-54, 172-175. London: Chapman and Hall, 1993.
16. Bohle, A., and Jocham, D. Intravesical immunotherapy with BCG: facts, figures and results, Chp. 5, pp. 18-32. Urban and Fischer Verlag Ed. Munchen, 2000.
17. Taniguchi, K., Koga, M., Nishikido, S., Yamashita, S., Sakuragi, T., Kanetake, H., and Saito, Y. Systemic immune response after intravesical instillation of Bacille Calmette-Guerin for superficial bladder cancer. Clin. Exp. Immunol., 115: 131-135, 1999.
18. Kaempfer, R., Gerez, L., Farbstein, H., Madar, L., Hirschman, O., Nussinovich, R., and Shapiro, A. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol., 14: 1778-1786, 1996.
19. Luo, Y., Chen, X., Downs, T. M., Dewolf, W. C., and O' Donnell, M. A. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis Bacillus Calmette-Guerin immunotherapy. J. Immunol., 162: 2399-2405, 1999.
20. Molto, L., Carballido, J., Manzano, L., Reyes, E., Olivier, C., and Alvarez-Mon, M. Prophylactic intracavitary treatment with interferon α increases interferon γ production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder. Br. J. Cancer, 75: 1849-1853, 1997.
21. Jackson, A. M., Hawkyard, S. J., Prescott, S., James, K., and Chisholm, G. D. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol. Immunother., 36: 25-30, 1993.
22. Jackson, A. M., Alexandrov, A. B., Prescott, S., James, K., and Chisholm, G. D. Expression of adhesion molecules by bladder cancer cells: modulation by interferon γ and tumor necrosis factor α. J. Urol., 148: 1583-1586, 1992.
23. Geboers, A. D. H., van Bergen, T. N. L. M., and Oosterlinck, W. γ-Interferon in the therapeutic and prophylactic management of superficial bladder cancer. J. Urol., 137: 276, 1987.
24. Hermanowicz, M., Marechal, J. M., Richaud, C., Ducassou, J., Cuzin, B., Chazarossian, E., Laurent, J. C., Poncelet, P., Lebreuil, G., Fontaniere, B., Brandely, M., and Avenard, G. Intravesical γ interferon in bladder carcinoma. Preliminary results. J. Interferon Res., 11 (Suppl. 1): 72, 1991.
25. Au, J. L., Badalament, R. A., Wientjes, G., Young, D. C., Warner, J. A., Venema, P. L., Pollifrone, D. L., Harbrecht, J. D., Chin, J. L., Lerner, S. P., and Miles, B. J. Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J. Natl. Cancer Inst. (Bethesda), 93: 597-604, 2001.
26. Martinez-Pineiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastian, J. L., Petrusa, C., Rioja, L. A., Martinez-Pineiro, L., Vela, R., Camacho, J. E., Nogueira, J. L., Resel, L., Muntanola, P., Galvis, F., Chesa, N., De Torres, J. A., Carballido, C., Bernuy, C., Arribas, S., Madero, R., and Club Urol. Espag. Tratam. Oncol. Long-term follow-up of a randomized prospective trial comparing a standard 81-mg dose of intravesical bacilli Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. Br. J. Urol. Int., 89: 671-680, 2002.
27. Bruno, S., Machi, A. M., Semino, C., Meta, M., Ponte, M., Varaldo, M., Curotto, A., Ferlazzo, G., Decensi, A., and Melioli, G. Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer. Cancer Immunol. Immunother., 42: 47-54, 1996.